BLOG

endpoints

Aveo teams with Bristol Myers after surprise FDA approval; CalciMedica lines up $21M raise to advance Covid-19 candidate

California-based CalciMedica closed a Series D round on Thursday to advance its portfolio of calcium release-activated calcium (CRAC) inhibitors, including Auxora, which is being tested in both Covid-19 and acute pancreatitis patients.